These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23260188)

  • 1. A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial.
    Scott PA; Meurer WJ; Frederiksen SM; Kalbfleisch JD; Xu Z; Haan MN; Silbergleit R; Morgenstern LB;
    Lancet Neurol; 2013 Feb; 12(2):139-48. PubMed ID: 23260188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
    Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
    Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
    Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X;
    Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
    Gusev EI; Martynov MY; Nikonov AA; Shamalov NA; Semenov MP; Gerasimets EA; Yarovaya EB; Semenov AM; Archakov AI; Markin SS;
    Lancet Neurol; 2021 Sep; 20(9):721-728. PubMed ID: 34418399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
    Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
    Anderson CS; Huang Y; Lindley RI; Chen X; Arima H; Chen G; Li Q; Billot L; Delcourt C; Bath PM; Broderick JP; Demchuk AM; Donnan GA; Durham AC; Lavados PM; Lee TH; Levi C; Martins SO; Olavarria VV; Pandian JD; Parsons MW; Pontes-Neto OM; Ricci S; Sato S; Sharma VK; Silva F; Song L; Thang NH; Wardlaw JM; Wang JG; Wang X; Woodward M; Chalmers J; Robinson TG;
    Lancet; 2019 Mar; 393(10174):877-888. PubMed ID: 30739745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.
    IST-3 collaborative group
    Lancet Neurol; 2013 Aug; 12(8):768-76. PubMed ID: 23791822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
    Logallo N; Novotny V; Assmus J; Kvistad CE; Alteheld L; Rønning OM; Thommessen B; Amthor KF; Ihle-Hansen H; Kurz M; Tobro H; Kaur K; Stankiewicz M; Carlsson M; Morsund Å; Idicula T; Aamodt AH; Lund C; Næss H; Waje-Andreassen U; Thomassen L
    Lancet Neurol; 2017 Oct; 16(10):781-788. PubMed ID: 28780236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial.
    Hanley DF; Lane K; McBee N; Ziai W; Tuhrim S; Lees KR; Dawson J; Gandhi D; Ullman N; Mould WA; Mayo SW; Mendelow AD; Gregson B; Butcher K; Vespa P; Wright DW; Kase CS; Carhuapoma JR; Keyl PM; Diener-West M; Muschelli J; Betz JF; Thompson CB; Sugar EA; Yenokyan G; Janis S; John S; Harnof S; Lopez GA; Aldrich EF; Harrigan MR; Ansari S; Jallo J; Caron JL; LeDoux D; Adeoye O; Zuccarello M; Adams HP; Rosenblum M; Thompson RE; Awad IA;
    Lancet; 2017 Feb; 389(10069):603-611. PubMed ID: 28081952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.
    Berge E; Cohen G; Roaldsen MB; Lundström E; Isaksson E; Rudberg AS; Slot KB; Forbes J; Smith J; Drever J; Wardlaw JM; Lindley RI; Sandercock PA; Whiteley WN;
    Lancet Neurol; 2016 Sep; 15(10):1028-34. PubMed ID: 27450474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
    Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
    Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
    Davis SM; Donnan GA; Parsons MW; Levi C; Butcher KS; Peeters A; Barber PA; Bladin C; De Silva DA; Byrnes G; Chalk JB; Fink JN; Kimber TE; Schultz D; Hand PJ; Frayne J; Hankey G; Muir K; Gerraty R; Tress BM; Desmond PM;
    Lancet Neurol; 2008 Apr; 7(4):299-309. PubMed ID: 18296121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
    Alexandrov AV; Köhrmann M; Soinne L; Tsivgoulis G; Barreto AD; Demchuk AM; Sharma VK; Mikulik R; Muir KW; Brandt G; Alleman J; Grotta JC; Levi CR; Molina CA; Saqqur M; Mavridis D; Psaltopoulou T; Vosko M; Fiebach JB; Mandava P; Kent TA; Alexandrov AW; Schellinger PD;
    Lancet Neurol; 2019 Apr; 18(4):338-347. PubMed ID: 30878103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial.
    Bracard S; Ducrocq X; Mas JL; Soudant M; Oppenheim C; Moulin T; Guillemin F;
    Lancet Neurol; 2016 Oct; 15(11):1138-47. PubMed ID: 27567239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
    Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
    JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
    Jones ML; Holmes M
    Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing Door-to-Needle Times for Ischaemic Stroke to a Median of 30 Minutes at a Community Hospital.
    Kamal N; Shand E; Swanson R; Hill MD; Jeerakathil T; Imoukhuede O; Heinrichs I; Bakker J; Stoyberg C; Fowler L; Duckett S; Holsworth S; Mann B; Valaire S; Bestard J
    Can J Neurol Sci; 2019 Jan; 46(1):51-56. PubMed ID: 30516454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.
    Hill MD; Goyal M; Menon BK; Nogueira RG; McTaggart RA; Demchuk AM; Poppe AY; Buck BH; Field TS; Dowlatshahi D; van Adel BA; Swartz RH; Shah RA; Sauvageau E; Zerna C; Ospel JM; Joshi M; Almekhlafi MA; Ryckborst KJ; Lowerison MW; Heard K; Garman D; Haussen D; Cutting SM; Coutts SB; Roy D; Rempel JL; Rohr AC; Iancu D; Sahlas DJ; Yu AYX; Devlin TG; Hanel RA; Puetz V; Silver FL; Campbell BCV; Chapot R; Teitelbaum J; Mandzia JL; Kleinig TJ; Turkel-Parrella D; Heck D; Kelly ME; Bharatha A; Bang OY; Jadhav A; Gupta R; Frei DF; Tarpley JW; McDougall CG; Holmin S; Rha JH; Puri AS; Camden MC; Thomalla G; Choe H; Phillips SJ; Schindler JL; Thornton J; Nagel S; Heo JH; Sohn SI; Psychogios MN; Budzik RF; Starkman S; Martin CO; Burns PA; Murphy S; Lopez GA; English J; Tymianski M;
    Lancet; 2020 Mar; 395(10227):878-887. PubMed ID: 32087818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
    Campbell BCV; Ma H; Ringleb PA; Parsons MW; Churilov L; Bendszus M; Levi CR; Hsu C; Kleinig TJ; Fatar M; Leys D; Molina C; Wijeratne T; Curtze S; Dewey HM; Barber PA; Butcher KS; De Silva DA; Bladin CF; Yassi N; Pfaff JAR; Sharma G; Bivard A; Desmond PM; Schwab S; Schellinger PD; Yan B; Mitchell PJ; Serena J; Toni D; Thijs V; Hacke W; Davis SM; Donnan GA;
    Lancet; 2019 Jul; 394(10193):139-147. PubMed ID: 31128925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.